Back

Impact of serum transthyretin levels during disease-modifying therapy with tafamidis on cardiac parameters and long-term outcomes in patients with transthyretin amyloid cardiomyopathy

29 August 2026 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Heart failure: diagnostics reimagined: electrocardiogram, artificial intelligence, and transthyretin amyloid cardiomyopathy Biomarkers ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Yuki Kubota

(Japan)

6 More presentations in this session

Presentation thumbnail
Electrocardiographic correlates of disease burden in cardiac transthyretin amyloidosis
Doctor T. Krammer (Regensburg, DE)
Abstract Slides Video
Presentation thumbnail
Assessment of transthyretin tetramer stability in patients with ATTR‑CM using a novel probe‑based immunoassay
Associate Professor M. Nagao (JP)
Abstract Slides Video
Presentation thumbnail
Myocardial work in light-chain and transthyretin-related amyloidosis with preserved ejection fraction: a cardiac magnetic resonance study
Doctor S. Liang (Chengdu, CN)
Abstract Slides Video
Presentation thumbnail
Determinants of circulating transthyretin levels across the clinical spectrum of transthyretin amyloidosis
Professor T. Tsuruda (Miyazaki, JP)
Abstract Slides Video
Presentation thumbnail
Circulating transthyretin tetramer as potential prognostic biomarker for outcome prediction in patients with heart failure
Doctor X. Zhang (Dalian, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure: diagnostics reimagined: electrocardiogram, artificial intelligence, and transthyretin amyloid cardiomyopathy

The Event

Event poster

ESC Congress 2026

29 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Beyond stability: unveiling the prognostic and therapeutic role of serum transthyretin in amyloid cardiomyopathy
31 August 2025
thumbnail
Congress Presentation
Differential effects of Tafamidis on cardiac remodelling in transthyretin amyloid cardiomyopathy: evidence from contemporary imaging data
28 August 2026
thumbnail
Congress Presentation
Ventricular arrhythmias in ATTR-CM: frequency, disease severity and risk of sudden cardiac death
28 August 2026
thumbnail
Congress Presentation
Vascular dysfunction is associated with symptom severity and quality of life in wild-type transthyretin amyloid cardiomyopathy
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources